植物及植物来源药物：全球市场

全球植物及植物来源药物市场预计将从 2025 年的 387 亿美元成长到 2030 年底的 581 亿美元，预测期内复合年增长率为 8.5%。

预计亚太地区市场规模将从2025年的131亿美元成长到2030年底的208亿美元，预测期内复合年增长率为9.6%。预计欧洲市场规模将从2025年的117亿美元成长到2030年底的175亿美元，预测期内复合年增长率为8.3%。

本报告考察了全球植物药和植物来源药物市场，并提供了市场概况、市场影响因素和市场机会分析、技术趋势、法律制度、市场规模趋势和预测、按各个细分市场和地区进行的详细分析以及主要企业的概况。

目录

第一章执行摘要

• 市场展望
• 调查范围
• 市场摘要
• 概述
• 当前市场情势
• 细分市场分析
• 新兴技术
• 结论

第二章 市场概览

• 概述
• 植物来源的历史
• 古埃及治疗方法（约西元前1500年）
• 传统中医（古代）
• 传统药局中的植物来源产品
• 奎宁：一种治疗疟疾的突破性药物，提取自金鸡纳树（17世纪）
• 阿斯匹灵：一种源自柳树皮的药物（19世纪）
• 植物药价值链
• 耕作与收穫
• 主要治疗
• 监管、製造和消费者
• 宏观经济因素分析
• 人口统计因素
• 地缘政治因素
• 美国关税的影响
• 波特五力分析

第三章 市场动态

• 市场动态
• 市场驱动因素
• 消费者对天然疗法的偏好正在改变
• 良好的安全性和耐受性
• 萃取、纯化和分析技术的进步
• 人口老化和慢性病日益增多
• 支持性的法规结构
• 市场限制
• 配置复杂且缺乏标准化
• 植物药研发经费不足
• 市场机会
• 植物代谢物在药物发现的应用
• 生物技术在个人化医疗发展的应用日益广泛

第四章：监理现状

• 概述
• 美国
• 欧洲
• 其他国家

第五章 新兴科技与发展

• 重点总结
• 单体学方法
• 多体学方法
• 发酵技术
• 管道分析
• 重点总结

第六章 市场区隔分析

• 细分市场分析
• 按产品类型分類的市场分析
• 重点总结
• 植物药
• 植物来源药物
• 按应用领域进行市场分析
• 重点总结
• 癌症
• 心血管疾病
• 中枢神经系统疾病
• 感染疾病
• 其他的
• 地理细分
• 区域市场分析
• 北美洲
• 欧洲
• 亚太地区
• 世界其他地区

第七章 竞争讯息

• 重点总结
• 竞争分析
• 大型製药企业
• 植物药公司
• 策略倡议

8. 植物及植物来源药物市场的永续性：ESG视角

• ESG简介
• 植物及植物来源药物产业的永续性趋势与倡议
• 结论

第九章附录

• 调查方法
• 来源
• 首字母缩写词
• 公司简介
• ANI PHARMACEUTICALS INC.
• BAYER AG
• BRISTOL-MYERS SQUIBB CO.
• CHIESI FARMACEUTICI SPA
• FRESENIUS KABI AG
• GSK PLC
• JAGUAR HEALTH
• JAZZ PHARMACEUTICALS INC.
• JOHNSON & JOHNSON
• MALLINCKRODT
• MEDIWOUND
• NOVARTIS AG
• PFIZER INC.
• SANOFI
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• 新兴Start-Ups/市场颠覆者

The global market for botanical and plant-derived drugs is expected to grow from $38.7 billion in 2025 and is projected to reach $58.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.5% during the forecast period of 2025 to 2030.

The Asia-Pacific market for botanical and plant-derived drugs is expected to grow from $13.1 billion in 2025 and is projected to reach $20.8 billion by the end of 2030, at a CAGR of 9.6% during the forecast period of 2025 to 2030.

The European market for botanical and plant-derived drugs is expected to grow from $11.7 billion in 2025 and is projected to reach $17.5 billion by the end of 2030, at a CAGR of 8.3% during the forecast period of 2025 to 2030.

Report Scope

The report provides an overview of the global market for botanical and plant-derived drugs and analyzes market trends. It includes global revenue ($ million) for 2024 as the base year data and estimated data for the forecast period, which is 2025 through 2030. The market is segmented based on product, application and region. By type, the market is segmented into plant-derived drugs and botanicals.

This report primarily focuses on drugs, rather than supplements or dietary substitutes. By application, the market is segmented into cancer, cardiovascular diseases, central nervous system disorders, infectious diseases and other. The regions covered in this study include North America, Europe, Asia-Pacific and the Rest of the World, with additional focus on major countries in these regions. North America includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain, and the Rest of Europe. The Asia-Pacific region includes China, Japan, India, South Korea, and the Rest of Asia-Pacific. Rest of the world includes South America and Middle East and Africa.

This report focuses on the significant driving trends and challenges that affect the market. It analyzes environmental, social, and corporate governance (ESG) developments. The report includes an analysis of the competitive landscape, with a focus on the key firms in the global market. It also has a dedicated section of company profiles that covers details such as overview, key financials, product portfolio and recent developments.

Report Includes

• 47 data tables and 47 additional tables
• An overview of the global market for botanical and plant-derived drugs
• In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
• Evaluation of the current market size and revenue growth prospects specific to the botanical and plant-derived drugs, accompanied by a market share analysis by type, application and region
• Analysis of current and future demand in the botanical and plant-derived drugs, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
• Detailed information on some of the botanical or plant products that have received FDA approval for prescription medications, such as Veregen and Fulyzaq, and a discussion of their therapeutic advantages over synthetic substitutes
• Analysis of drivers, challenges and opportunities affecting market growth
• Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
• Market share analysis of the key market participants of the industry, along with their research priorities, product portfolios, global rankings and competitive landscape
• Profiles of major companies within the industry, including Bayer, Novartis, Jaguar Health Inc., Jazz Pharmaceuticals, and Bristol Myers Squibb Co.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Overview
• Current Market Scenario
• Segmental Analysis
• Emerging Technologies
• Conclusion

Chapter 2 Market Overview

• Overview
• History of Plant-Derived Medicines
• Ancient Egyptian Healing Practices (Circa 1500 BCE)
• Chinese Herbal Medicine (Ancient times)
• Plant-Derived Products in the Traditional Pharmacopeias
• Quinine: A Malaria Breakthrough from Cinchona (17th Century)
• Aspirin: A Gift from the Willow Tree (19th Century)
• Botanical Drugs Value Chain
• Cultivation and Collection
• Primary Processing
• Regulatory, Manufacturing and Consumers
• Macroeconomic Factors Analysis
• Demographic Factors
• Geopolitical Factors
• Impact of U.S. Tariffs
• Porter's Five Forces Analysis
• Potential of New Entrants: Moderate to High
• Bargaining Power of Suppliers: Moderate to High
• Bargaining Power of Buyers: Moderate
• Threat of Substitute Products or Services: Moderate
• Level of Competitiveness: High

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Shift in Consumer Preference for Natural-Origin Therapeutics
• Favorable Safety and Tolerability Profile
• Advances in Extraction, Purification, and Analytical Technologies
• Aging Population and the Growing Prevalence of Chronic Diseases
• Supportive Regulatory Frameworks
• Market Restraints
• Complex Composition and Lack of Standardization
• Lack of Funding for Botanical Drugs R&D
• Market Opportunities
• Application of Plant Metabolites for Drug Discovery
• Growing Biotechnological Integration for Personalized Medicine Development

Chapter 4 Regulatory Landscape

• Overview
• U.S.
• Europe
• Other Countries

Chapter 5 Emerging Technologiesand Developments

• Key Takeaways
• Single-Omics Approaches
• Multi-Omics Approaches
• Fermentation Technology
• Pipeline Analysis
• Key Takeaways

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Analysis by Product Type
• Key Takeaways
• Botanical Drugs
• Plant-Derived Drugs
• Market Analysis by Application
• Key Takeaways
• Cancer
• Cardiovascular Diseases
• Central Nervous System Disorders
• Infectious Diseases
• Others
• Geographic Breakdown
• Market Analysis by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Key Takeaways
• Competitive Analysis
• Large Pharmaceutical Companies
• Botanical Drug Companies
• Strategic Initiatives

Chapter 8 Sustainability in the Botanical and Plant-Derived Drugs Market: An ESG Perspective

• Introduction to ESG
• Sustainability Trends and Initiatives of the Botanical and Plant-Derived Drugs Industry
• Concluding Remarks

Chapter 9 Appendix

• Research Methodology
• Sources
• Acronyms
• Company Profiles
• ANI PHARMACEUTICALS INC.
• BAYER AG
• BRISTOL-MYERS SQUIBB CO.
• CHIESI FARMACEUTICI S.P.A.
• FRESENIUS KABI AG
• GSK PLC
• JAGUAR HEALTH
• JAZZ PHARMACEUTICALS INC.
• JOHNSON & JOHNSON
• MALLINCKRODT
• MEDIWOUND
• NOVARTIS AG
• PFIZER INC.
• SANOFI
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• Emerging Start-ups/Market Disruptors

List of Tables

• Summary Table : Global Market for Botanical and Plant-Derived Drugs, by Region, Through 2030
• Table 1 : Important Natural Products Derived from Plants
• Table 2 : Global Incidence and Mortality Cancer Rates, by WHO Region, 2022
• Table 3 : Natural Products Classified as Medicines in Different Jurisdictions
• Table 4 : EU Regulation of Herbal Medicinal Products
• Table 5 : Regulation of Herbal Medicinal Products
• Table 6 : Botanical Drugs in Development
• Table 7 : Global Market for Botanical and Plant-Derived Drugs, by Product Type, Through 2030
• Table 8 : Global Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 9 : Global Market for Cancer Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
• Table 10 : Global Market for Cardiovascular Disease Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
• Table 11 : Global Market for Central Nervous System Disorder Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
• Table 12 : Global Market for Infectious Disease Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
• Table 13 : Global Market for Other Applications in Botanical and Plant-Derived Drugs, by Region, Through 2030
• Table 14 : Global Market for Botanical and Plant-Derived Drugs, by Region, Through 2030
• Table 15 : North American Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 16 : North American Market for Botanical and Plant-Derived Drugs, by Country, Through 2030
• Table 17 : U.S. Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 18 : Canadian Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 19 : Mexican Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 20 : European Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 21 : European Market for Botanical and Plant-Derived Drugs, by Country, Through 2030
• Table 22 : Percentage of Indications for Using Herbal Medicines in Germany
• Table 23 : German Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 24 : U.K. Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 25 : French Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 26 : Spanish Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 27 : Italian Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 28 : Rest of Europe Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 29 : Asia-Pacific Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 30 : Asia-Pacific Market for Botanical and Plant-Derived Drugs, by Country, Through 2030
• Table 31 : Chinese Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 32 : Japanese Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 33 : Indian Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 34 : South Korean Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 35 : Rest of Asia-Pacific Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 36 : Rest of the World Market for Botanical and Plant-Derived Drugs, by Application Type, Through 2030
• Table 37 : Rest of the World Market for Botanical and Plant-Derived Drugs, by Sub-Region, Through 2030
• Table 38 : Strategic Initiatives in the Botanical and Plant-Derived Drugs Market, 2021-2025
• Table 39 : Information Sources in this Report
• Table 40 : Abbreviations Used in the Botanical and Plant-Derived Drugs Market
• Table 41 : ANI Pharmaceuticals Inc.: Company Snapshot
• Table 42 : ANI Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
• Table 43 : ANI Pharmaceuticals Inc.: Product Portfolio
• Table 44 : Bayer AG: Company Snapshot
• Table 45 : Bayer AG: Financial Performance, FY 2023 and 2024
• Table 46 : Bayer AG: Product Portfolio
• Table 47 : Bayer AG: News/Recent Developments, 2024-2025
• Table 48 : Bristol-Myers Squibb Co.: Company Snapshot
• Table 49 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
• Table 50 : Bristol-Myers Squibb Co.: Product Portfolio
• Table 51 : CHIESI Farmaceutici S.p.A.: Company Snapshot
• Table 52 : CHIESI Farmaceutici S.p.A.: Financial Performance, FY 2023 and 2024
• Table 53 : CHIESI Farmaceutici S.p.A.: Product Portfolio
• Table 54 : CHIESI Farmaceutici S.p.A.: News/Key Developments, 2023
• Table 55 : Fresenius Kabi AG: Company Snapshot
• Table 56 : Fresenius Kabi AG: Financial Performance, FY 2023 and 2024
• Table 57 : Fresenius Kabi AG: Product Portfolio
• Table 58 : GSK plc: Company Snapshot
• Table 59 : GSK plc: Financial Performance, FY 2023 and 2024
• Table 60 : GSK plc: Product Portfolio
• Table 61 : GSK plc: News/Key Developments, 2022
• Table 62 : Jaguar Health: Company Snapshot
• Table 63 : Jaguar Health: Financial Performance, FY 2023 and 2024
• Table 64 : Jaguar Health: Product Portfolio
• Table 65 : Jaguar Health: News/Key Developments, 2023-2025
• Table 66 : Jazz Pharmaceuticals Inc.: Company Snapshot
• Table 67 : Jazz Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
• Table 68 : Jazz Pharmaceuticals Inc.: Product Portfolio
• Table 69 : Jazz Pharmaceuticals Inc.: News/Key Developments, 2021
• Table 70 : Johnson & Johnson: Company Snapshot
• Table 71 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
• Table 72 : Johnson & Johnson: Product Portfolio
• Table 73 : Mallinckrodt: Company Snapshot
• Table 74 : Mallinckrodt: Financial Performance, FY 2023 and 2024
• Table 75 : Mallinckrodt: Product Portfolio
• Table 76 : MediWound: Company Snapshot
• Table 77 : MediWound: Financial Performance, FY 2023 and 2024
• Table 78 : MediWound: Product Portfolio
• Table 79 : MediWound: News/Key Developments, 2022-2024
• Table 80 : Novartis AG: Company Snapshot
• Table 81 : Novartis AG: Financial Performance, FY 2023 and 2024
• Table 82 : Novartis AG: Product Portfolio
• Table 83 : Novartis AG: News/Key Developments, 2024
• Table 84 : Pfizer Inc.: Company Snapshot
• Table 85 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
• Table 86 : Pfizer Inc.: Product Portfolio
• Table 87 : Sanofi: Company Snapshot
• Table 88 : Sanofi: Financial Performance, FY 2023 and 2024
• Table 89 : Sanofi: Product Portfolio
• Table 90 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
• Table 91 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
• Table 92 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
• Table 93 : List of a Few Emerging Startups in the Botanical and Plant-Derived Drugs Market

List of Figures

• Summary Figure : Global Market Shares of Botanical and Plant-Derived Drugs, by Region, 2024
• Figure 1 : Botanical Drugs Value Chain
• Figure 2 : Porter's Five Forces Analysis of the Botanical and Plant-Derived Drugs Market
• Figure 3 : Market Dynamics of Botanical and Plant-Derived Drugs
• Figure 4 : Global Market Shares of Botanical and Plant-Derived Drugs, by Product Type, 2024
• Figure 5 : Global Market Shares of Botanical and Plant-Derived Drugs, by Application Type, 2024
• Figure 6 : Global Market Shares of Botanical and Plant-Derived Drugs, by Region, 2024
• Figure 7 : North American Market Shares of Botanical and Plant-Derived Drugs, by Country, 2024
• Figure 8 : European Market Shares of Botanical and Plant-Derived Drugs, by Country, 2024
• Figure 9 : Asia-Pacific Market Shares of Botanical and Plant-Derived Drugs, by Country, 2024
• Figure 10 : Rest of the World Market Shares of Botanical and Plant-Derived Drugs, by Sub-Region, 2024
• Figure 11 : ANI Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 12 : ANI Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 13 : Bayer AG: Revenue Shares, by Business Unit, FY 2024
• Figure 14 : Bayer AG: Revenue Shares, by Country/Region, FY 2024
• Figure 15 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
• Figure 16 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
• Figure 17 : CHIESI Farmaceutici S.p.A.: Revenue Shares, by Business Unit, FY 2024
• Figure 18 : CHIESI Farmaceutici S.p.A.: Revenue Shares, by Country/Region, FY 2024
• Figure 19 : Fresenius Kabi AG: Revenue Shares, by Business Unit, FY 2024
• Figure 20 : GSK plc: Revenue Shares, by Business Unit, FY 2024
• Figure 21 : GSK plc: Revenue Shares, by Country/Region, FY 2024
• Figure 22 : Jaguar Health: Revenue Shares, by Business Unit, FY 2024
• Figure 23 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 24 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 25 : Johnson & Johnson: Revenue Shares, by Business Unit, FY 2024
• Figure 26 : Johnson & Johnson: Revenue Shares, by Country/Region, FY 2024
• Figure 27 : Mallinckrodt: Revenue Shares, by Business Unit, FY 2024
• Figure 28 : Mallinckrodt: Revenue Shares, by Country/Region, FY 2024
• Figure 29 : MediWound: Revenue Shares, by Country/Region, FY 2024
• Figure 30 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
• Figure 31 : Novartis AG: Revenue Shares, by Country/Region, FY 2024
• Figure 32 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 33 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 34 : Sanofi: Revenue Shares, by Country/Region, FY 2024
• Figure 35 : Teva Pharmaceutical Industries Ltd.: Market Shares, by Country/Region, FY 2024